Trials / Completed
CompletedNCT01229865
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the safety and evaluate the response of VB-111 on DTC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VB-111 |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2014-10-01
- Completion
- 2016-06-01
- First posted
- 2010-10-28
- Last updated
- 2018-10-23
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01229865. Inclusion in this directory is not an endorsement.